J&J's McNeil begins RFP process for Tylenol franchise

FORT WASHINGTON, PA: Johnson & Johnson's McNeil Consumer Healthcare business has issued an RFP for consumer PR work for its Tylenol franchise.

FORT WASHINGTON, PA: Johnson & Johnson's McNeil Consumer Healthcare business has issued an RFP for consumer PR work for its Tylenol franchise.

The pharmaceutical company, which is in the early stages of the RFP process, is having “conversations with some agency partners on aspects” of the Tylenol business, said Barbara Montresor, VP of corporate communications at McNeil Consumer Healthcare.

Montresor added that McNeil is at the “early onset of having issued an RFP to begin those conversations” so it is difficult to say what title the winning agency would have or to define the scope of work.  

She added that the company is “going to continue to work with other agency partners on other aspects of the business.”

In February, Tylenol issued a major recall of the brand's entire infant product line, which was followed by the departure of Johnson & Johnson CEO Bill Weldon in April. Former Vice Chair Alex Gorsky succeeded Weldon.

J&J also said in April that some of its products, including infant Tylenol, eight-hour Tylenol, Pepcid Complete, and Simply Sleep, may be unavailable on store shelves until next year to give the company time to resolve manufacturing issues associated with previous recalls.

Last month, Hakan Erdemir, J&J's VP of operations for over-the-counter products at McNeil, left the division. He was named in the 2011 government legal action accusing the company of manufacturing deficiencies at McNeil plants, which reportedly caused recalls. Now based in Switzerland, Erdemir is serving as VP of planning for J&J consumer products in Europe, the Middle East, and Asia.  

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.